@ron_alfa Profile picture

Ron Alfa

@ron_alfa

CEO/Co-founder, @NOETIK_AI | Previously SVP, Head of Research @RecursionPharma $RXRX | @StanfordMed Neuroscience MD-PhD | @PDSoros | Build the Future

Similar User
Chris Gibson photo

@RecursionChris

Viswa Colluru photo

@viswacolluru

Recursion photo

@RecursionPharma

Amee Kapadia photo

@ameekapadia

Bits in Bio photo

@bitsinbio

Patrick Malone, MD PhD photo

@patricksmalone

Enveda photo

@lifeschemistry

Tess van Stekelenburg photo

@velvetatom

Alex Telford photo

@Atelfo

Zavain Dar photo

@zavaindar

David Li photo

@davidycli

Alfredo Andere photo

@AlfredoAndere

Pablo Lubroth photo

@pablolubroth

Altitude Lab photo

@AltitudeLab

Gleb Kuznetsov photo

@glebkuz

Pinned

1/ @NOETIK_ai team are live at #SITC24 showing off new biological discoveries using our foundation models for human cellular and tissue biology. Come along for a tour:

Tweet Image 1

Cooking high heat.

Founder mode is on a lower heat setting in biotech than in tech today but it’s still cooking. Don’t sleep on it



100%. Pharmacology is commoditized.

This is 100% coming to all of biotech, if not already here Also not happening just at early clinical stage … Discovery is similar. In China, standing start to DC with desired molecule target profile in ~18 mo For US biotechs there had better be some novel biology or more…



Ron Alfa Reposted

Today we report Evo, a generalist foundation model for biology, on the cover of @ScienceMagazine Trained on billions of DNA nucleotides, Evo was designed to capture two key aspects of biology: the multi-modality of the central dogma and the multi-scale nature of evolution.

A new Science study presents “Evo”—a machine learning model capable of decoding and designing DNA, RNA, and protein sequences, from molecular to genome scale, with unparalleled accuracy. Evo’s ability to predict, generate, and engineer entire genomic sequences could change the…

Tweet Image 1


Beat me to it.

My investment thesis for 2025 after today: monoclonal antibodies for measles, polio, and other preventable diseases



Breakthroughs in biology World Models at @NOETIK_ai to simulate patient biology for drug discovery and translation.

A New Kid On the Block: AI World Models In Biotech open.substack.com/pub/andriibuva…



Ron Alfa Reposted

1/ This is the next chapter of a story about courageous patients and their families, of multidisciplinary teamwork, and hard-fought steps forward to effective therapy for #DIPG #DMG, a universally lethal cancer of the brain and spinal cord. 🧵nature.com/articles/s4158…


Ron Alfa Reposted

Today the emotions are many but words are few. I’ll save the latter for a longer post soon. Let’s go @lifeschemistry ! 🚀

This one is special… We have advanced our first drug into Phase 1 clinical trials! ENV-294 is a first-in-class small molecule with exciting potential to treat atopic dermatitis (commonly known as eczema) – an underserved and devastating inflammatory condition that impacts more…



Training this week: single cell spatial transcriptomics + tumor whole exome seq, 1000 patients 500M parameters, 96 H100s


now alphafold3 is open: 👏 x.com/maxjaderberg/s…

Totally agree, differential data is key in bio. We see this with new protein models that benchmark to AlphaFold emerging on an almost weekly basis. Outside of PDB, public datasets are inadequate for serious ML.



Our slack is often crazy awesome images with understated comments. “The re-scans look pretty good.”

Tweet Image 1

Ron Alfa Reposted

Many biotech "lives" worth celebrating... calculated risk-taking by teams and investors in a quest to bring new medicines to patients... that, in the end, weren't successful. RIP so many biotechs worthy of our appreciation...


Loading...

Something went wrong.


Something went wrong.